CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 868 enrolled
Drug / intervention
Intanza +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01665807
NCT01665807Phase 4Completed
CompareCT.gov

A Time-Motion Study to Compare Self-vaccination With Intanza® Intradermal Influenza Vaccine to Nurse-administered Vaxigrip® Intramuscular Influenza Vaccine in Small Group Settings of Health Care Workers

Brenda Coleman·interventional·Posted Aug 15, 2012·Updated Apr 19, 2017

In Brief

A Phase 4 clinical trial evaluating Intanza and Vaxigrip for Influenza and Vaccination Site Reactions (HT). Completed, enrolled 868 participants across 2 sites.

Detailed Summary

The investigators hypothesize that people working in an acute care hospital setting will be able to successfully self-administer the intradermal vaccine (Intanza) in less time than nurse-administration of the regular intramuscular influenza vaccine (Vaxigrip). The investigators also hypothesize that people administering the intradermal vaccine for the second time will take less time to successfully administer than people administering it for the first time.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza, Vaccination Site Reactions (HT)
CountriesCanada
CollaboratorsSanofi Pasteur, a Sanofi Company

Timeline

Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedAug 15, 2012
Enrollment StartSep 1, 2012
Primary CompletionDec 1, 2012
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 13.9 years ago

Interventions

Intanzabiological

Intanza influenza vaccine, trivalent split-virion, inactivated, approved for the 2012-2013 influenza season in northern hemisphere

Vaxigripbiological

Influenza vaccine, trivalent, split-virion, inactivated, approved for the 2012-2013 influenza season in the northern hemisphere